Both low- and high-MW chitosan can reduce liver gluconeogenesis, as evidenced by inhibiting the expression of gluconeogenesis-related enzyme, phosphoenolpyruvate carboxykinase (PEPCK), thus ameliorating abnormal glucose and insulin profiles in STZ-induced T1DM rats [55]. This evidence concerns the gene INS and type 1 diabetes mellitus.